A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.
Primary Care Provider that sees diabetes patients in clinic
Provider does not see patients with Diabetes
Parallel
Intensive Prevention Strategy
BehavioralProviders randomized to the intensive prevention strategy will receive notification about patients with diabetes who have high heart failure risk and recommendations for medical management, e-consultation, or referral to a cardiometabolic risk management program.
Incident Heart Failure or All-cause death
Incident Heart Failure (based on electronic health record International Classification of Diseases codes) or all-cause death. This will be assessed via retrospective chart review.
Prescription Rates of SGLT2i
Counts of SGLT2 inhibitor prescriptions filled
Prescription Rate of Finerenone
Counts of Finerenone prescriptions
Prescription Rate of GLP1
Counts of GLP1 prescription
Click on the lead sponsor to view all of their trials.
University of Texas Southwestern Medical Center
Lead sponsor
Roche Diagnostics GmbH
Collaborator
